Literature DB >> 31771341

Predictive Model for Mortality Risk Including the Wound, Ischemia, Foot Infection Classification in Patients Undergoing Revascularization for Critical Limb Ischemia.

Nobuyoshi Azuma1, Mitsuyoshi Takahara2, Akio Kodama3, Yoshimitsu Soga4, Hiroto Terashi5, Junichi Tazaki6, Terutoshi Yamaoka7, Atsuhiro Koya1, Osamu Iida8.   

Abstract

BACKGROUND: The aim of this study was to develop a predictive model for mortality risk based on preoperative risk factors, including the Wound, Ischemia, Foot Infection (WIfI) classification, in patients undergoing revascularization for critical limb ischemia.
METHODS: We analyzed a database of the Surgical reconstruction versus Peripheral Intervention in Patients With Critical Limb Ischemia registry, a multicenter, prospective, observational study that included 520 critical limb ischemia patients (192 surgical and 328 endovascular patients).
RESULTS: Multivariate Cox regression analysis identified old age, impaired mobility, low body mass index, renal failure, heart failure, and high WIfI grade as independent risk factors for all-cause mortality (all P<0.05). The risk score comprising these risk factors discriminated the mortality risk well; the 2-year survival rate was >90% in the first quantile of the risk score and ≈20% in the fifth quantile. The area under the time-dependent receiver operating characteristics curve was 0.829 for thirty-day mortality and 0.811 for 2-year mortality. Adding more detailed preoperative information to the predictive model revealed that cystatin C-based estimated glomerular filtration rate, left ventricular ejection fraction, and cholinesterase levels were additional independent risk factors, but the predictive accuracy of the model was not significantly improved, according to the time-dependent receiver operating characteristics curve and net reclassification improvement.
CONCLUSIONS: The current study developed a risk score for mortality using preoperative risk factors, including the WIfI classification, in critical limb ischemia patients undergoing revascularization.

Entities:  

Keywords:  ambulation difficulty; body mass index; foot ulcer; heart failure; kidney failure; peripheral arterial disease; survival analysis

Mesh:

Year:  2019        PMID: 31771341     DOI: 10.1161/CIRCINTERVENTIONS.119.008015

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  5 in total

1.  The Impact of Chronic Limb-Threatening Ischemia on Cardiac Surgery.

Authors:  Naohiro Wakabayashi; Shinsuke Kikuchi; Naoya Kuriyama; Yuta Kikuchi; Masahiro Tsutsui; Hayato Ise; Yuri Yoshida; Daiki Uchida; Atsuhiro Koya; Tomonori Shirasaka; Nobuyoshi Azuma; Hiroyuki Kamiya
Journal:  Front Surg       Date:  2022-04-28

2.  Current and Past Obesity in Japanese Patients with Critical Limb Ischemia Undergoing Revascularization.

Authors:  Mitsuyoshi Takahara; Osamu Iida; Yoshimitsu Soga; Akio Kodama; Hiroto Terashi; Nobuyoshi Azuma
Journal:  J Atheroscler Thromb       Date:  2020-03-19       Impact factor: 4.928

3.  The perioperative and long-term fates of patients with chronic limb-threatening ischaemia who underwent secondary major amputations.

Authors:  Tomoe Ogaki; Osamu Iida; Yosuke Hata; Natsumi Yamauchi; Chika Yokoi; Mitsuyoshi Takahara; Hiroto Terashi; Toshiaki Mano; Yuji Asada
Journal:  Int Wound J       Date:  2021-05-16       Impact factor: 3.315

4.  Ambulatory Status Over Time after Revascularization in Patients with Chronic Limb-Threatening Ischemia.

Authors:  Akio Kodama; Mitsuyoshi Takahara; Osamu Iida; Yoshimitsu Soga; Hiroto Terashi; Daizo Kawasaki; Yuichi Izumi; Shinsuke Mii; Kimihiro Komori; Nobuyoshi Azuma
Journal:  J Atheroscler Thromb       Date:  2021-05-27       Impact factor: 4.394

5.  Impact of homocysteine levels on mortality risk in patients with chronic limb-threatening ischemia undergoing revascularization.

Authors:  Mitsuyoshi Takahara; Osamu Iida; Yoshimitsu Soga; Akio Kodama; Hiroto Terashi; Nobuyoshi Azuma
Journal:  Heart Vessels       Date:  2021-06-15       Impact factor: 2.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.